Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-Xa assays.
Research output: Contribution to journal › Article
Apixaban is an oral direct factor Xa inhibitor developed for prophylaxis and treatment of thromboembolic disorders. Laboratory monitoring is not necessary, but the effects on common coagulation reagents and assays are clinically valuable information.
|Research areas and keywords||
Subject classification (UKÄ) – MANDATORY
|Journal||Journal of Thrombosis and Haemostasis|
|Publication status||Published - 2014|